CureMatch is the first and only company to provide a comprehensive decision support system ranking personalized combination therapy options SAN DIEGO, CA – March 7, 2017 –CureMatch today announced the launch of their decision support software platform for the selection of combinations of cancer-fighting drugs; personalized for individual patients based on the molecular profile of […]
Press
The Latest From CureMatch
San Diego Xconomy editor Bruce Bigelow discusses the CureMatch product launch and CEO Blaise Barrelet’s personal cancer story.
CureMatch Announces New Advances in Using Metabolomic Profiling to Distinguish Among Cancer Subtypes
This Discovery is Expected to Pave the Way for Metabolomic Profiling in the Monitoring and Treatment of Cancer SAN DIEGO, CA – February 23, 2017 – CureMatch, the developer of a decision support platform for combination therapy in cancer, revealed in the 2nd Annual Biomarker Conference new discoveries using metabolomics as a tool for clinical […]
Next-generation sequencing study validates a core principle behind the CureMatch technology SAN DIEGO, CA – February 16, 2017 – CureMatch, the developer of a decision support platform for combination therapy in cancer, today announced that research from their co-founder and Chief Medical Advisor, Dr. Razelle Kurzrock, was selected by the American Society of Clinical Oncology […]
OncoImmunology Publication Validates Need to Determine Specific Subset of Mutations that Elicit Cancer Therapy Response SAN DIEGO, CA – February 7, 2017 – CureMatch, the developer of a Decision Support System for combination therapy in cancer, today revealed in the peer-reviewed journal OncoImmunology the description of a specific mechanism that can potentially be used for selecting […]
© 2019 CureMatch, Inc. CureMatch is a registered trademark.